Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.
Rigel Provides Business Update and 2025 Outlook
Jan 13, 2025 · Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results …
Mar 4, 2025 · Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.
Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL)
Jan 22, 2025 · Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Rigel Announces R289 Granted Fast Track Designation by the FDA …
Dec 2, 2024 · SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the…
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for ...
Oct 24, 2024 · Healthcare providers and patients are encouraged to report adverse events in patients taking GAVRETO to the Rigel Medical Communications Center at 1-800-983-1329 or producthelp@rigel.com. You may also report adverse events associated with taking GAVRETO directly to the FDA.
Rigel Announces R289 Granted Orphan Drug Designation by the …
Jan 9, 2025 · SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the…
Rigel Reports First Quarter 2024 Financial Results and Provides ...
May 7, 2024 · First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA® net product sales of $4.9 million Expanded Rigel's portfolio with acquisition of…
Products :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.